Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | FLT4 | P35916 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.30 |
| ▸ | TEK | Q02763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31748388 | 0.81 | KLKB1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31748413 | 0.80 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL31748692 | 0.80 | DGAT1 (0.34) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31748544 | 0.78 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL31748311 | 0.77 | EGFR (0.33) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31748486 | 0.76 | DGAT1 (0.33) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL1049931 | 0.74 | KRAS (0.41) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL31748345 | 0.72 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL20422563 | 0.71 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL29514195 | 0.71 | DGAT1 (0.39) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | DGAT1 3043/4885EGFR 833/4885IGF1R 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.